Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers
Background: Approximately 6% of women with breast cancer carry pathogenic germline variants in predisposition genes such as BRCA1 and BRCA2. Depending on personal and family cancer history, it is therefore recommended to test for hereditary breast cancer. Moreover, as shown by the phase III OlympiA...
Main Authors: | Dominik Dannehl, Tobias Engler, Léa Louise Volmer, Christian Martin Tegeler, Julia Fusshoeller, Emma Gabrysch, Kenneth Eissler, Anna Seller, Eva-Maria Grischke, Markus Hahn, Ines Gruber, Fabienne Schochter, Kerstin Pfister, Kristina Veselinovic, Elena Leinert, Brigitte Rack, Visnja Fink, Wolfgang Janni, Sara Yvonne Brucker, Andreas Daniel Hartkopf, Henning Schäffler |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/15/3847 |
Similar Items
-
BRCA2 reversion mutation confers resistance to olaparib in breast cancer
by: Shinya Yamamoto, et al.
Published: (2023-06-01) -
Olaparib in the metastatic HER2-negative breast cancer setting
by: L. G. Zhukova, et al.
Published: (2020-12-01) -
Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy
by: Toko Kumeta, et al.
Published: (2019-10-01) -
The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers
by: Henning Schäffler, et al.
Published: (2023-11-01) -
Profile of olaparib in the treatment of advanced ovarian cancer
by: Chase DM, et al.
Published: (2016-04-01)